Clinical trials
Prostate Cancer Stage clinical trials
Below are recruiting prostate cancer stage clinical trials, each written for real people, not researchers. We’re tracking 410 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT06305832RecruitingPhase 2
Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Nanjing, JiangsuAges 40 years+ - NCT06320223Recruiting
PSMA PET scan registry for prostate cancer outcomes
This registry collects information from people with prostate cancer who have had a PSMA PET scan. Researchers want to learn how well this scan predicts outcomes over at least 3 years, which may help improve future care.
EssenAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT06834204Enrolling by invitation
Better care coordination for cancer survivors
This study tests a program to improve communication between your cancer team and your regular doctor. If you have heart or diabetes risks and you're being treated for breast, prostate, bladder, or endometrial cancer, this trial may help coordinate your care.
New Brunswick, New JerseyAges 18 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT06335693Recruiting
Short-course radiation after prostate surgery
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06347705RecruitingPhase 2
Vaccine plus standard therapy for prostate cancer before surgery
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
Basking Ridge, New JerseyAges 18 years+ - NCT06388122Recruiting
Blood test study for HR+ breast cancer treatment monitoring
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
Jacksonville, FloridaAges 18 years+ - NCT06389786Recruiting
Using a new PET scan to find cancer spread before prostate surgery
This trial tests a special PET/MRI scan that may help doctors see if prostate cancer has spread to nearby lymph nodes before surgery. It could help guide treatment decisions for men with high-risk prostate cancer.
Jacksonville, FloridaAges 30–85 - NCT06391034RecruitingPhase 2
MRI scan with pyruvate for prostate cancer
This trial uses a special MRI scan (with hyperpolarized pyruvate, a naturally occurring substance) to look at prostate cancer in more detail. It aims to help doctors understand how the cancer is responding to treatment or how it might behave.
San Francisco, CaliforniaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06437574RecruitingPhase 2
Cholesterol-lowering and immune response in prostate cancer
This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06451445Recruiting
Focal IRE treatment for intermediate-risk prostate cancer
This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.
Toronto, OntarioAges 50 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT06474806RecruitingPhase 2
PET scan for untreated prostate cancer
This trial tests a new type of PET scan that looks for a protein called uPAR on prostate cancer cells. It might help doctors see your cancer more clearly without needing surgery or treatment first.
Herlev, CopenhagenAges 18 years+ - NCT06484361RecruitingPhase 2
PET/MRI scan for prostate cancer staging before surgery
This trial tests whether a special PET/MRI scan can better see the extent of prostate cancer before surgery. It aims to help doctors plan more precise treatment.
MilanAges 18 years+ - NCT04945642Recruiting
Radiation combination therapy for intermediate to high-risk prostate cancer
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
Los Angeles, CaliforniaAges 18 years+ - NCT06491056Recruiting
Focal therapy study for prostate cancer in Asia
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
SingaporeAges 40–85 - NCT06500169Recruiting
Golf exercise study for prostate cancer survivors
This study tests if golf can help men with prostate cancer feel better and stay healthy. It's for men who are on hormone therapy and want to try a gentle, fun exercise.
Los Angeles, CaliforniaAges 55–85 - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+
Hear when a new Prostate Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer stage?
- Yes. Clin2 currently lists 410 recruiting prostate cancer stage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer stage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer stage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.